CME

Podcast

Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

This Oncology PER®Spectives™ podcast examines the recent advancements in the treatment landscape for advanced melanoma. In this activity, experts Yana Najjar, MD; Rahul A. Sheth, MD, FSIR; and Douglas Johnson, MD, MSCI, discuss the challenges of immune checkpoint inhibitor resistance and the practical strategies for overcoming this by using direct intratumoral injections of oncolytic viral immunotherapies, which rely on close interdisciplinary collaboration between medical oncologists and interventional radiologists.

Target Audience

This educational activity is directed toward a primary target audience of interventional radiologists and a secondary target audience of medical oncologists, nurse practitioners, physician assistants, and nurses who treat patients with advanced melanoma.

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Replimune Group, Inc.

Faculty:

Yana Najjar, MD

Associate Professor of Medicine
Director, Clinical and Translational Research Center
UPMC Hillman Cancer Center
Pittsburgh, PA

Disclosures: Speakers’ Bureau: Immunocore, Pfizer; Adviser: Bristol Myers Squibb, Immunocore, Merck, Novartis, Pfizer, Replimune, Therakos

Douglas B. Johnson, MD, MSCI

Co-Leader, Translational Research and Interventional Oncology Research Program
Professor of Medicine (Hematology/Oncology)
Clinical Director, Melanoma Vanderbilt-Ingram Medical Center
Nashville, TN

Disclosures: Consultant: Jackson Labs, Teiko; Advisory Board: AstraZeneca, Bristol Myers Squibb, Merck, Pfizer

Rahul A. Sheth, MD, FSIR

Associate Professor, Department of Interventional Radiology, Division of Diagnostic Imaging
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Boston Scientific; Consultant: Boston Scientific, Inari Medical, Johnson & Johnson, Medtronic, NanOlogy, Replimune, TriSalus Life Sciences

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

June 5, 2025

Expiration Date

June 5, 2026

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity